NVX-757

NVX-757 is a Novavax investigational **recombinant RSV-F protein particle vaccine** developed for prevention of respiratory syncytial virus infection. Public trial records identify it as a Phase 1 vaccine candidate evaluated in healthy adults, where multiple RSV-F formulations were compared against placebo for safety and immunogenicity. Based on the publicly available study descriptions, NVX-757 is a protein-based prophylactic vaccine intended to present the RSV fusion protein antigen and induce protective anti-RSV immune responses; a precise single molecular target or detailed formulation-specific mechanism beyond RSV-F antigen immunization is not clearly described in the accessible source excerpts.

Other names

RSV-F Particle Vaccinerespiratory syncytial virus fusion protein particle vaccinerecombinant RSV-F protein particle vaccine